Coherus BioSciences (CHRS) Annoucnes CHS-1701 Immunogenicity Study Met All Endpoints
Tweet Send to a Friend
Coherus BioSciences, Inc. (NASDAQ: CHRS) announced that CHS-1701, a proposed biosimilar of Neulasta® (pegfilgrastim), met both primary endpoints in a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
